1. Home
  2. BOLT vs SURG Comparison

BOLT vs SURG Comparison

Compare BOLT & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLT
  • SURG
  • Stock Information
  • Founded
  • BOLT 2015
  • SURG 2006
  • Country
  • BOLT United States
  • SURG United States
  • Employees
  • BOLT N/A
  • SURG N/A
  • Industry
  • BOLT Biotechnology: Pharmaceutical Preparations
  • SURG Advertising
  • Sector
  • BOLT Health Care
  • SURG Consumer Discretionary
  • Exchange
  • BOLT Nasdaq
  • SURG Nasdaq
  • Market Cap
  • BOLT 22.6M
  • SURG 25.8M
  • IPO Year
  • BOLT 2021
  • SURG N/A
  • Fundamental
  • Price
  • BOLT $0.44
  • SURG $1.37
  • Analyst Decision
  • BOLT Hold
  • SURG Buy
  • Analyst Count
  • BOLT 5
  • SURG 2
  • Target Price
  • BOLT $1.25
  • SURG $8.50
  • AVG Volume (30 Days)
  • BOLT 105.0K
  • SURG 102.2K
  • Earning Date
  • BOLT 03-20-2025
  • SURG 03-18-2025
  • Dividend Yield
  • BOLT N/A
  • SURG N/A
  • EPS Growth
  • BOLT N/A
  • SURG N/A
  • EPS
  • BOLT N/A
  • SURG N/A
  • Revenue
  • BOLT $9,779,000.00
  • SURG $83,602,653.00
  • Revenue This Year
  • BOLT $9.87
  • SURG N/A
  • Revenue Next Year
  • BOLT N/A
  • SURG $59.69
  • P/E Ratio
  • BOLT N/A
  • SURG N/A
  • Revenue Growth
  • BOLT 35.86
  • SURG N/A
  • 52 Week Low
  • BOLT $0.42
  • SURG $1.05
  • 52 Week High
  • BOLT $1.56
  • SURG $7.03
  • Technical
  • Relative Strength Index (RSI)
  • BOLT 36.26
  • SURG 49.86
  • Support Level
  • BOLT $0.42
  • SURG $1.05
  • Resistance Level
  • BOLT $0.48
  • SURG $1.34
  • Average True Range (ATR)
  • BOLT 0.03
  • SURG 0.10
  • MACD
  • BOLT -0.00
  • SURG 0.01
  • Stochastic Oscillator
  • BOLT 16.00
  • SURG 72.79

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About SURG SurgePays Inc.

Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; Lead Generation is a generation and case management solutions company serving law firms in the mass tort industry; and Others. It generates the revenue from Mobile Virtual Network Operator segment.

Share on Social Networks: